Takeda allies with Resolve to develop autoimmune disease drugs

03/1/2013 | Genetic Engineering & Biotechnology News

Takeda Pharmaceutical and Resolve Therapeutics agreed to collaborate on treatments for systemic lupus erythematosus and other autoimmune disorders, with an initial focus on Resolve's nuclease Fc fusion protein RSLV-132. The deal gives Takeda an exclusive option to license all Resolve compounds following a study on RSLV-132. Resolve will get $8 million for clinical development, a potential option exercise payment and as much as $247 million in milestone fees plus sales royalties.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA